Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms (PROGIS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Novartis
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: February 17, 2011
Last updated: March 6, 2014
Last verified: March 2014
This study will access the GI complaints on patients reported outcomes and to determine the improvement in quality of life in patients.

Kidney Transplantation
GI Symptoms Severity

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Open, Multi-centre, Non-interventional, Observational Study to Characterize the Impact That GI Complaints Have on Patient-reported Outcomes in Patients Who Have Had a Renal Transplant. Patients Will be Evaluated at Visit 1 and Then Again After 4 (+2) Weeks (Visit 2)

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To determine if GI symptoms severity and health related quality of life of patients has improved after being converted from MMF to EC-MPS due to GI complaints. [ Time Frame: 4-6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To identify and evaluate quality of life and impact on symptom severity based on patients perception. [ Time Frame: 4-6 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: July 2010
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
With Gastro-Intestinal (GI) symptoms
Without GI symptoms


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Kidney transplanted Patients currently on MMF who have GI symptoms and will be converted to EC-MPS treatment and patients currently on MMF without GI symptoms who will continue with MMF therapy.

Inclusion Criteria:

  • Patient received kidney transplant at least 1 month prior to study with MMF as a part of the treatment for at least 2 weeks.
  • Eligible to convert to myfortic because of GI complaints or not currently experiencing GI complaints and stable on current immunosuppressive regimen.
  • At least 18 years of age;
  • Willing to provide written informed consent; and
  • Able to meet all study requirements including completing paper questionnaires and completing two study visits.

Exclusion Criteria:

  • GI symptoms assumed or known not be caused by MPA therapy and have recent acute rejection at least 1 week prior to the study.
  • Breast-feeding or pregnant woman.
  • Patients with psychiatric illness.
  • Underlying acute medical intervention or hospitalization
  • Receiving investigational drug within 30days prior to study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01300416

Contact: Novartis Pharmaceuticals +41-61-324-1111

Hospital Universiti Kebangsaan Malaysia Recruiting
Cheras, Malaysia
Hospital Raja Perempuan Zainab II Recruiting
Kota Bharu, Malaysia
Hospital Queen Elizabeth Recruiting
Kota Kinabalu, Malaysia
Hospital Kuala Lumpur Recruiting
Kuala Lumpur, Malaysia
Hospital Tengku Ampuan Afzan Recruiting
Kuantan, Malaysia
Hospital Umum Sarawak Recruiting
Kuching, Malaysia
Hospital Pulau Pinang Recruiting
Pulau Pinang, Malaysia
Hospital Selayang Recruiting
Selayang, Malaysia
Hospital Serdang Recruiting
Serdang, Malaysia
Sponsors and Collaborators
Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals ) Identifier: NCT01300416     History of Changes
Other Study ID Numbers: CERL080AMY02 
Study First Received: February 17, 2011
Last Updated: March 6, 2014
Health Authority: Malaysia: Ministry of Health Malaysia

Keywords provided by Novartis:
Kidney transplantation
mycophenolate sodium
Health Related Quality of Life
GI symptoms
GIQLI processed this record on February 11, 2016